RenovoRx
RNXTRenovoRx is a commercial-stage life sciences company focused on developing and commercializing targeted oncology therapies through its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
Profile
RenovoRx is a commercial-stage life sciences company focused on developing and commercializing targeted oncology therapies through its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform. The company's core value proposition is the precise delivery of therapeutic agents across arterial walls directly to solid tumors, aiming to increase local drug concentration while minimizing systemic toxicity compared to traditional intravenous chemotherapy.
A growth-stage innovator in locoregional drug delivery with a patented platform that addresses hypovascular tumors resistant to standard chemoembolization.
Questions, answered.
- What is RenovoRx's market cap?
- RenovoRx (RNXT) has a market capitalization of $42.4M and trades on NASDAQ.
- Who are RenovoRx's competitors?
- RenovoRx's key competitors include TriSalus Life Sciences, Novocure, Revolution Medicines, and others. These companies compete in similar markets and product categories.
- Who does RenovoRx partner with?
- RenovoRx's notable partners include Medical Murray, Inc., Novocure.
- Where is RenovoRx headquartered?
- RenovoRx is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.